FSL2 Post Approval Study for Pediatric and Young Adults Patients

Launched by ABBOTT DIABETES CARE · Jul 9, 2021

Keywords

ClinConnect Summary

The FSL2 Post Approval Study is a clinical trial designed to evaluate the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System for managing diabetes in children and young adults aged 4 to 30 years. This study will help researchers understand how well this device works for people with type 1 or type 2 diabetes who have been diagnosed for at least three months. To participate, individuals must currently use a method to check their blood sugar, understand English, and be able to follow study instructions.

Participants in this study will be monitored while using the FreeStyle Libre system, which helps track glucose levels without needing to do frequent finger pricks. It's important to note that individuals who have used a continuous glucose monitoring system in the past six months, are pregnant, or have certain medical conditions may not be eligible to join. The study is actively recruiting participants, and the information collected will contribute to better diabetes management for young patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject must be 4 - 30 years of age.
• • 2. Subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment.
• • 3. Subject is currently using Self Monitoring of Blood Glucose (SMBG) for managing their diabetes.
• • 4. Subject has completed participation in clinical study ADC-US-PMS-20194 or has at least six (6) months of medical history hypoglycemia or hyperglycemia requiring healthcare professional intervention.
• • 5. Subject and/or caregiver must be able to read and understand English.
• • 6. In the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
• • 7. Subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate.
• Exclusion Criteria:
• • 8. Subject has previously used a continuous glucose monitoring system to manage their diabetes within the last six (6) months.
• • 9. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
• • 10. Subject is known to be pregnant or is attempting to become pregnant at the time of enrollment.
• • 11. Subject is on dialysis at the time of enrollment.
• • 12. Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff.
• • 13. Subject currently is participating in another clinical trial.
• • 14. Subject is unsuitable for participation due to any other cause as determined by the Investigator.